



PRACTICE BULLETIN

CLINICAL MANAGEMENT GUIDELINES FOR OBSTETRICIAN—GYNECOLOGISTS

NUMBER 110, JANUARY 2010

(Replaces Committee Opinion Number 337, June 2006)

Noncontraceptive Uses of Hormonal Contraceptives

More than 80% of U.S. women will use hormonal contraception during their reproductive years (1). Many of these women use hormonal contraception for its noncontraceptive benefits. Hormonal contraceptives can correct menstrual irregularities resulting from oligo-ovulation or anovulation and make menstruation more predictable.

The purpose of this document is to describe noncontraceptive uses for hormonal contraceptives and examine the evidence evaluating the effectiveness of contraceptives for these applications. For many of the conditions, experts suggest that effects of contraceptives are class effects and that all formulations may provide similar therapy. Evidence will be given for specific routes and formulations of hormonal contraception when available, although there are few data on newer methods and formulations.

Background

Patients are often unaware of the noncontraceptive benefits of hormonal contraception, and this represents an opportunity for counseling (2). A brief list of some common noncontraceptive benefits is provided in Box 1.

Most hormonal contraceptives combine a progestin for its contraceptive effects and an estrogen to stabilize the endometrium and reduce unwanted spotting. Users of progestin-only hormonal contraceptives avoid the side effects associated with the use of contraceptives containing estrogen. Progestin-only contraceptives often can be used in women when estrogen is contraindicated; however, unpredictable spotting may be problematic for some patients. Over time, this unwanted bleeding generally subsides and progestin-only methods may provide highly effective long-term contraception.

Since oral contraceptives containing 150 micrograms of mestranol were introduced in 1960, the dose of estrogen per pill has been reduced; currently, pills may con-

Box 1. Potential Noncontraceptive Benefits of Hormonal Contraception

- Menstrual cycle regularity
- Treatment of menorrhagia
- Treatment of dysmenorrhea
- Inducing amenorrhea for lifestyle considerations
- Treatment of premenstrual syndrome
- Prevention of menstrual migraines
- Decrease in risk of endometrial cancer, ovarian cancer, and colorectal cancer
- Treatment of acne or hirsutism
- Improved bone mineral density
- Treatment of bleeding due to leiomyomas
- Treatment of pelvic pain due to endometriosis

Committee on Practice Bulletins—Gynecology. This Practice Bulletin was developed by the Committee on Practice Bulletins—Gynecology with the assistance of Robert L. Reid, MD. The information is designed to aid practitioners in making decisions about appropriate obstetric and gynecologic care. These guidelines should not be construed as dictating an exclusive course of treatment or procedure. Variations in practice may be warranted based on the needs of the individual patient, resources, and limitations unique to the institution or type of practice.

tain as little as 20 micrograms of estrogen. It is unclear whether the trend toward using lower doses of hormonal contraception in the past three decades has reduced any of the noncontraceptive benefits of hormonal contraception.

New progestins with less androgenicity and triphasic preparations designed to reduce overall progestin exposure have resulted in changes to the progestin constituents of the combined oral contraceptive (OC) (3). Other pills contain drospirenone or cyproterone acetate, which have additional antiandrogenic properties.

There is inadequate published evidence to determine whether triphasic combined OCs differ from monophasic combined OCs in effectiveness, bleeding patterns, or discontinuation rates (4). Triphasic preparations have been shown to reduce acne (5), decrease the incidence of ectopic pregnancy, reduce menstrual blood loss, and lower frequency of irregular bleeding and menorrhagia (6). Low-dose and triphasic preparations do not as effectively prevent the development of benign ovarian cysts as did high-dose monophasic preparations (7–9).

The contraceptive patch has comparable efficacy to combined OCs and as such would be expected to reduce ectopic pregnancy, regulate and reduce bleeding, and diminish dysmenorrhea. The extended cycle patch has been used to reduce menstrual cycle-related side effects, including menstrual migraine (10, 11). Also, the contraceptive patch has effects on androgenic markers that compare favorably with combined OCs (12) and, therefore, positive effects on androgenic conditions such as acne should be expected. The contraceptive intravaginal ring is reported to be effective for dysmenorrhea and premenstrual dysphoric disorder (13, 14). There is little published information on the noncontraceptive benefits of progestin contraceptive implants (15). The levonorgestrel intrauterine system is a highly effective contraceptive method with significant noncontraceptive benefits in women with excessive menstrual bleeding and dysmenorrhea. Numerous studies have confirmed the effectiveness of the levonorgestrel intrauterine system for reduction of menstrual blood loss in idiopathic menorrhagia, adenomyosis (16, 17), leiomyomas (18, 19), pain due to endometriosis (20–22), and hemostatic disorders (23) with commensurate reductions in dysmenorrhea and anemia (17, 24).

Clinical Considerations and Recommendations

► *Which hormonal contraceptives are beneficial for treatment of dysmenorrhea?*

Dysmenorrhea is pain resulting from intense uterine contractions that are triggered by the release of endometrial

prostaglandins. Dysmenorrhea is the most commonly reported menstrual disorder, affecting up to 90% of young women (25). Combined oral contraceptives have been shown to reduce uterine prostaglandin production and to relieve dysmenorrhea in up to 70–80% of women. Small randomized controlled trials (RCTs) (26, 27) and survey data (28) demonstrate a clear reduction in dysmenorrhea among women who use combined OCs. In addition, an RCT comparing the contraceptive intravaginal ring to a combined OC containing 30 micrograms of ethinyl estradiol and 3 mg of drospirenone found reductions in dysmenorrhea in both groups (from 17.4% to 5.9% in the ring group and 19% to 6.4% in the combined OC group) (13).

The single-rod contraceptive progestin implant also appears to reduce dysmenorrhea in most users (29). One study reported a decrease in the number of women with dysmenorrhea from 59% at baseline to 21% after treatment (30). Of those women who reported a history of dysmenorrhea at baseline, 81% showed improvement with progestin contraceptive implant use. Another study reported a 35% incidence of dysmenorrhea among participants at baseline, with 82% of these women reporting improvement in symptoms after progestin contraceptive implant use (31). Data on the effects of the levonorgestrel intrauterine system for dysmenorrhea are limited, but given that this device reduces or eliminates menstruation for many women, the positive benefits reported seem consistent with the mechanism of action (32).

Limited data suggest that combined OCs can reduce the severity of dysmenorrhea in women with endometriosis (33). Continuous combined OCs may offer additional benefit by elimination of menstruation and associated dysmenorrhea. Both depot medroxyprogesterone acetate (DMPA) and the progestin contraceptive implant have been shown to reduce pain due to endometriosis (34, 35). Several trials have demonstrated the efficacy of the levonorgestrel intrauterine system in treating dysmenorrhea and chronic pelvic pain associated with endometriosis (20, 21, 36, 37).

► *Which hormonal contraceptives are beneficial for cycle control?*

Combined hormonal contraceptives can correct menstrual irregularities resulting from oligo-ovulation or anovulation and make menstruation more predictable. Extended cycle regimens, including 84-day continuous combined OC followed by a 7-day hormone-free interval, can further reduce scheduled bleeding associated with hormonal contraceptives but may be associated with higher rates of spotting and other unscheduled bleeding in the first months of therapy (38).

Most clinical trials have demonstrated that unscheduled spotting or light bleeding is common in the first 3–6 months with all combined OCs. Women using hormonal contraception for menstrual regulation should be counseled about this possible effect.

The progestin-only pill is thought to inhibit ovulation in approximately 50% of women (39, 40). The remainder of women using this method will continue to menstruate regularly. Other progestin-only methods (DMPA and levonorgestrel intrauterine system) initially result in increased rates of unscheduled bleeding but lead to diminished blood loss over time as a substantial number of women using these methods become amenorrheic.

Evaluation of a continuous daily regimen of 90 micrograms of levonorgestrel per 20 micrograms of ethinyl estradiol demonstrated that 79% reported absence of bleeding by pack 13 with the incidence of breakthrough bleeding decreasing progressively from initiation (41). Several pills also are available that extend the active pills to 24 days (1 mg of norethindrone acetate per 20 micrograms of ethinyl estradiol followed by four placebo pills and 3 mg of drospirenone per 20 micrograms of ethinyl estradiol followed by four placebo pills). The drospirenone-containing pill has been shown in a randomized trial to reduce the symptoms of premenstrual syndrome (42), and it has been approved by the U.S. Food and Drug Administration for treatment of premenstrual dysphoric disorder and acne.

Women on cyclic hormonal contraception may experience premenstrual symptoms as well as distressing symptoms (including pelvic pain, headaches, breast tenderness, and bloating) in the hormone-free interval (38, 43). Extending the usual 21-day cycle of contraceptive pills (41, 44, 45) was shown to reduce pelvic pain and headaches while improving overall mood (46). Extended use of the contraceptive patch (10) and the contraceptive ring (47) affords similar benefits. Such regimens are one way to avoid menstrual-related symptoms or to delay menstruation for women who anticipate inconvenient menstrual bleeding during travel or important life events.

A progestin injection (DMPA) or progestin contraceptive implant would not be ideal for short-term induction of amenorrhea because of the unpredictable bleeding associated with early use. A substantial number of women using the levonorgestrel intrauterine system and DMPA will achieve amenorrhea. These methods could be considered for long-term menstrual suppression if immediate amenorrhea is not desired, if there is a contraindication to an estrogen containing contraceptive, or if long-term contraception is desired.

► ***What is the evidence supporting hormonal contraceptive use as an alternative to surgical therapy for menorrhagia?***

Excessive menstrual bleeding (60–80 mL per cycle or greater) if untreated can lead to iron deficiency anemia (48). It has been estimated to occur in approximately 10% of women of reproductive age, although as many as 30% of women will seek treatment for this condition (48–50). Combined hormonal contraceptives can reduce excessive menstrual bleeding in most affected women and are considered a reasonable option for initial management of menorrhagia. This is particularly true in women who may desire future fertility because the contraceptive effect is readily reversible.

Menstrual blood loss is reduced by 40–50% in women who used cyclic combined OCs (51–53). The effectiveness of combined OCs may be enhanced by extended cycle or continuous therapies that reduce the number of total bleeding episodes (54, 55). Extended cycle and continuous combined OCs as well as many of the progestin-only contraceptive options (progestin-only pills, DMPA, progestin contraceptive implants, and levonorgestrel intrauterine system) reduce overall bleeding days and may achieve amenorrhea in many women (45, 56). Clinical trials with the single-rod progestin contraceptive implant have demonstrated that the irregular bleeding typical of progestin-only methods occurs in the first 3 months, with amenorrhea resulting in 30% and 40% of women at 1 year (29, 57). Reductions in blood loss of up to 86% after 3 months and up to 97% after 12 months of use have been reported with the levonorgestrel intrauterine system (58–61). At 12 months after insertion of the levonorgestrel intrauterine system, reported rates of amenorrhea vary between 20% and 80% (62–65).

A Cochrane review examined the effectiveness of the levonorgestrel intrauterine system compared with oral cyclical norethindrone for treatment of heavy menstrual bleeding (66). The report concluded that the levonorgestrel intrauterine system is a more effective treatment, and that women with a levonorgestrel intrauterine system are more satisfied and willing to continue with treatment. However, these women do experience more side effects, such as intermenstrual bleeding and breast tenderness. A systematic review and meta-analysis found that both the levonorgestrel intrauterine system and endometrial ablation were associated with similar reductions in menstrual blood loss up to 24 months, and both treatments were generally associated with similar improvements in quality of life (67). Progestogenic side effects were greater in women using the levonorgestrel intrauterine system, and serious side effects occurred more often in those receiving surgical intervention (66, 68).

Markov modeling has been used to estimate the cost-effectiveness of different approaches to management of menorrhagia in women desiring contraception (69). In the absence of a pathological cause, the use of a combined OC for menorrhagia was the most cost-effective approach in the first year only. In women who responded initially to a combined OC, it was more cost-effective to switch to a levonorgestrel device than to continue with combined OCs. In women who failed to respond to combined OCs, the levonorgestrel intrauterine system was the most cost-effective approach followed by surgery if the levonorgestrel intrauterine system also failed (69).

► ***Which hormonal contraceptives are beneficial for treatment of premenstrual syndrome (PMS) and premenstrual dysphoric disorder?***

The first systematic studies to examine the effects of combined OCs on PMS found little difference in PMS symptoms between combined OC users and nonusers (70, 71). In addition, there were no significant differences between agents with differing progestational potencies (72). Monophasic and triphasic preparations showed similar rates of symptomatology (73).

Premenstrual dysphoric disorder, a severe form of PMS, is a condition that adversely affects the psychological well-being and social interactions of some 3–5% of women of reproductive age (74). The only RCTs to demonstrate improvement in symptoms of premenstrual dysphoric disorder have involved a combined OC with a 24/4 regimen containing 30 micrograms of ethinyl estradiol with drospirenone as the progestogenic component (42, 75, 76). These trials have been shown to offer relief from both physical and psychological manifestations of premenstrual dysphoric disorder with improvement in health-related quality of life.

A direct comparison of a drospirenone containing combined OC with the intravaginal contraceptive ring reported equivalent improvement in PMS (13). Combined OCs containing 30 micrograms of ethinyl estradiol with 3 mg of drospirenone also have been shown to decrease premenstrual mood deterioration in reproductive-aged women receiving treatment for depression (77). Another approach that appears to be helpful for PMS is to suppress menstruation and stabilize hormones with extended cycle or continuous combined OC regimens (78).

► ***Which hormonal contraceptives are beneficial for treatment of menstrual migraines?***

Sixty percent of women with migraines link attacks to menstruation. Documented menstrual migraine occurs in 8–14% of women (79–81). These migraines are experienced exclusively at the time of menstruation and these

women are virtually free of migraine at other times of the cycle, with the exception of the small percentage of women who experience a brief exacerbation associated with ovulation. The use of extended cycle or continuous hormonal contraception (including combined OCs, the patch, and DMPA) reduces or eliminates the hormonal fluctuations thought to precipitate migraine attacks and thereby may afford relief of migraine headaches for some women (11, 79, 82).

Although cerebrovascular events occur rarely among women with migraines who use combined OCs, the impact of a stroke is so devastating that clinicians should consider progestin-only, intrauterine, or barrier contraceptives for women who experience migraine with focal neurological signs, or those who smoke or who are 35 years or older.

► ***Which hormonal contraceptives are effective for treatment of hirsutism and acne?***

All combined OCs have the potential to improve hirsutism and acne because they all increase sex hormone binding globulin and suppress luteinizing hormone-driven ovarian androgen production, thereby reducing the levels of free androgen, which initiate and maintain the acne and hair growth. Although hormonal therapy can prevent an increase in hirsutism, existing hair will need to be permanently removed.

In a small RCT, a drospirenone and ethinyl estradiol combination was as effective as cyproterone acetate combined with ethinyl estradiol in improving hirsutism (83). Another small RCT compared second generation combined OCs containing levonorgestrel with third generation combined OCs containing desogestrel. This trial found that both formulations were effective in improving hirsutism (84).

A Cochrane review evaluated 23 trials on the effects of combined OCs on acne: 5 placebo-controlled trials, 17 trials comparing different combined OC regimens, and 1 trial comparing a combined OC to an antibiotic (85). Combined OCs reduced both inflammatory and noninflammatory facial acne lesions as determined by acne lesion counts, severity grades, and self-assessed acne compared with placebo. Few differences were found between type of OCs and effectiveness for acne treatment. Differences in the comparative effectiveness of combined OCs containing varying progestin types and dosages were less clear although combined OCs containing antiandrogenic progestins (drospirenone or cyproterone acetate) were superior in some comparative trials.

Hormonal contraceptive methods that bypass the first-pass liver effects of the OC (the contraceptive patch and the vaginal contraceptive ring) may have a lesser effect on sex hormone binding globulin. Progestin-only methods are not normally considered effective for acne.

► ***What is the role of hormonal contraceptives in decreasing cancer risk?***

Endometrial Cancer

Strong epidemiological evidence supports a 50% reduction in the risk of endometrial cancer among women who have used combined OCs compared with women who have never used combined OCs (86–91). The Cancer and Steroid Hormone Study confirmed that both short-term (less than 5 years) and long-term (equal to or greater than 5 years) use of combined OCs resulted in similar reductions in risk (92). Longer durations of use were associated with greater decreases in risk to as low as an odds ratio of 0.2 (93, 94). This effect lasts for up to 20 years (95). Overall deaths from endometrial cancer were significantly reduced in past OC users (HR 0.2) (96). Limited data suggest that risk reduction persists with new formulations and lower dose combined OCs (90). Some studies have found a reduction in endometrial cancer regardless of the progestin potency of the combined OC (97) whereas others found a greater risk reduction in those combined OCs with highest progestin potency (88, 98). Depot medroxyprogesterone acetate shows a similar protective effect on subsequent development of endometrial cancer (99, 100).

The levonorgestrel intrauterine system achieves concentrations in the endometrium several hundred-fold higher than achieved with traditional systemic therapy (101). The levonorgestrel intrauterine system is now approved as the progestin component of postmenopausal hormone therapy in some countries (102). Accordingly, investigators have examined its use for medical treatment of endometrial hyperplasia (103–105). A systematic review found the levonorgestrel intrauterine system to be an effective treatment for hyperplasia without atypia (regression in 96%) (106). However, accurate diagnosis and ongoing surveillance are essential. For women with hyperplasia with atypia, data on the effect of the levonorgestrel intrauterine system are limited to small case series. Therefore, it is unclear whether the levonorgestrel intrauterine system is effective for treatment of atypical hyperplasia. All investigators have emphasized the importance of continuing endometrial surveillance to detect cases where atypical hyperplasia persists or progresses. Reports of endometrial cancer developing despite use of the levonorgestrel intrauterine system suggest the need for caution with this approach (107). Endometrial sampling can never ensure that the most advanced disease is identified, and the risk of missed endometrial adenocarcinoma is significant (108). The levonorgestrel intrauterine system also has been shown to protect the endometrium in women taking tamoxifen for adjuvant breast cancer therapy (109).

Ovarian Cancer

A collaborative reanalysis of worldwide data on combined OCs and ovarian cancer involving 45 epidemiological studies with 23,000 ovarian cancer cases and 87,000 controls has demonstrated that every use of combined OC decreases the risk of ovarian cancer by 27% (110). The longer the duration of combined OC use, the greater the risk reduction, amounting to a decrease of approximately 20% for every 5 years of use. The protective effect has been shown to extend to low-dose pills (111). Some have suggested that combined OCs be used as a form of chemoprotection against ovarian cancer by women with *BRCA* gene mutations (112).

Colorectal Cancer

A meta-analysis of 6 cohort and 14 case-control studies reported an 18% reduction in the risk of developing colorectal cancer among OC users. This reduction was greatest for recent use and showed no duration effect (113). The Royal College of General Practitioners' Oral Contraception Study also suggested that current or recent, but not past, use of combined OCs conferred a lower risk of colorectal cancer, although none of the findings reached statistical significance (114).

► ***Can hormonal contraceptives prevent or be used to treat ovarian cysts?***

By preventing ovulation, hormonal contraception should reduce the findings of follicular and corpus luteal cysts on ultrasound examination as suggested by the results of small case series reports (115). Such cysts are rarely of clinical significance although they may lead to unnecessary repeat ultrasound studies when discovered incidentally. Not all follicular activity is suppressed with low-dose OCs, and small ovarian cysts are common in users of these formulations (7–9). Case-control studies have failed to demonstrate a difference in the rate of detection of functional ovarian cysts in women using either monophasic or triphasic combined OCs (116).

The follicle-stimulating hormone-induced suppression of hormonal contraceptives would seem to be an ideal way to accelerate the spontaneous regression of larger functional ovarian cysts. However, available research does not support this notion. In a series of RCTs in women of reproductive age, the use of combined OCs did not hasten the resolution of functional ovarian cysts compared with expectant management (117–120). Therefore combined OCs should not be used to treat existing functional ovarian cysts.

Older studies demonstrated that asymptomatic unruptured follicular cysts may occur in 10–20% of cycles in women using progestin-only pills (121). Users of progestin contraceptive implants, although anovulatory,

may experience formation of ovarian cysts (122). Most of these cysts are asymptomatic and resolve spontaneously.

► ***Do hormonal contraceptives have an effect on bone mass and fracture risk?***

Estrogen is a powerful inhibitor of bone resorption. Because fractures related to fragile bone occur infrequently in young women, surrogate markers such as bone mineral density (BMD) are often used to evaluate the effects of hormonal contraception on bone. However, BMD provides information on only one facet of bone health, and its use to predict future fracture risk in young hormonal contraceptive users has not been validated (123).

Oral contraceptives have been reported to have beneficial effects or no effect on BMD (124–128). Combined OC use is associated with increased bone density among women in the later reproductive years, with longer duration of use (greater than 10 years) being associated with greater BMD (124, 125, 129, 130). It has been suggested that combined OC use at times of estrogen deficiency may reduce subsequent fracture risk (131). Although one systematic review concluded that there was fair evidence that combined OCs increased BMD, other data led to the conclusion that adolescent and young adult women who use combined OC will have lower BMD than nonusers (132–134). Higher calcium intake may provide protection in this circumstance (135). Combined OC use in perimenopausal and postmenopausal women preserved bone mass, whereas nonusers lost BMD (131).

A Cochrane review examined the effect of hormonal contraception on fracture risk and found no RCTs examining fracture as an outcome (136). They reported on three observational studies that found no effect of combined OCs on risk of fracture (137–139), three studies with a significantly increased risk of fracture among combined OC users (140–142), and three studies reporting a protective effect for combined OC use (143–145). Most of the studies did not specify the formulation of the combined OCs, and none provided results specifically for users of low-dose formulations.

They also concluded from a range of studies examining the effects of combined OCs on BMD that combined OCs did not appear to affect BMD or biochemical markers of bone turnover (136). The evidence for other combined hormonal methods is limited, with one study suggesting that BMD is lower among premenopausal users of etonogestrel and ethinyl estradiol vaginal rings than in nonusers (134). Because the BMD was within one standard deviation of the untreated controls, this result was felt to lack clinical significance (146).

Several studies have found decreased BMD in users of DMPA and progestin implants (147–149). Additional

data raise concern that DMPA followed by low-dose OC pill use (20 micrograms of ethinyl estradiol) may slow bone recovery (150). Bone loss during contraceptive use may be analogous to that which occurs with breastfeeding and is rapidly recovered (151, 152). Past users of DMPA, including women who used DMPA after 40 years of age show similar BMD to that in women who never used DMPA (153). No data exist on fracture risk among postmenopausal women who previously used DMPA.

► ***Does combined OC use affect the development of leiomyomas? Is there a role for combined OCs or levonorgestrel intrauterine systems in the treatment of leiomyomas?***

The precise effects of combined OCs on the formation and growth of uterine leiomyomas remain poorly understood. Case–control studies have reported no effect (154) or reduced risk (155, 156) of leiomyomas among combined OC users. Two large cohort studies found that neither current nor past combined OC use was associated with the risk of developing leiomyomas (157, 158).

Data are limited about the effects of estrogen and progestin treatment of leiomyomas. Estrogen and progestin treatment may control bleeding symptoms without stimulating further leiomyoma growth. However, studies of progestin therapy have demonstrated mixed results. Although several small studies have shown a decrease in leiomyoma size during progestin therapy, other studies using progestin therapy alone or in conjunction with a gonadotropin-releasing hormone agonist identify an increase in leiomyoma volume or uterine volume during therapy (159). The levonorgestrel intrauterine system has been shown to reduce overall uterine volume with little or no effect on the size of leiomyomas (32, 160).

Based on the limited data available it appears overall that combined OCs and the levonorgestrel intrauterine system have little effect on the development of uterine leiomyomas (18).

Summary of Recommendations and Conclusions

The following recommendations are based on good and consistent scientific evidence (Level A):

- Combined OCs should not be used to treat existing functional ovarian cysts.
- Use of combined hormonal contraception has been shown to decrease the risk of endometrial and ovarian cancer.

- ▶ Combined OCs have been shown to regulate and reduce menstrual bleeding, treat dysmenorrhea, reduce premenstrual dysphoric disorder symptoms, and ameliorate acne.
- ▶ Continuous combined hormonal contraception, DMPA, and the levonorgestrel intrauterine system may be considered for long-term menstrual suppression.

The following recommendations are based on limited or inconsistent scientific evidence (Level B):

- ▶ Based on the limited data available it appears overall that combined OCs do not increase the risk of development of uterine leiomyomas.
- ▶ Hormonal contraception should be considered for the treatment of menorrhagia in women who may desire further pregnancies.

Proposed Performance Measure

Percentage of women using hormonal contraception for symptomatic relief of menorrhagia or dysmenorrhea or both who have no contraindications and wish to preserve reproductive function

References

1. Piccinino LJ, Mosher WD. Trends in contraceptive use in the United States: 1982-1995. *Fam Plann Perspect* 1998; 30:4-10, 46. (Level II-3)
2. Kaunitz AM. Oral contraceptive health benefits: perception versus reality. *Contraception* 1999;59:29S-33S. (Level III)
3. David PS, Boatwright EA, Tozer BS, Verma DP, Blair JE, Mayer AP, et al. Hormonal contraception update. *Mayo Clin Proc* 2006;81:949-54; quiz 955. (Level III)
4. Grimes DA, Lopez LM, Schulz KF, Van Vliet HA, Helmerhorst FM. Triphasic versus monophasic oral contraceptives for contraception. *Cochrane Database of Systematic Reviews* 2006, Issue 3. Art. No.: CD003553. DOI: 10.1002/14651858.CD003553.pub2. (Meta-analysis)
5. Redmond GP, Olson WH, Lippman JS, Kafriksen ME, Jones TM, Jorizzo JL. Norgestimate and ethinyl estradiol in the treatment of acne vulgaris: a randomized, placebo-controlled trial. *Obstet Gynecol* 1997;89:615-22. (Level I)
6. Cedars MI. Triphasic oral contraceptives: review and comparison of various regimens. *Fertil Steril* 2002;77: 1-14. (Level III)
7. Lanes SF, Birmann B, Walker AM, Singer S. Oral contraceptive type and functional ovarian cysts. *Am J Obstet Gynecol* 1992;166:956-61. (Level II-2)
8. Young RL, Snabes MC, Frank ML, Reilly M. A randomized, double-blind, placebo-controlled comparison of the impact of low-dose and triphasic oral contraceptives on follicular development. *Am J Obstet Gynecol* 1992;167:678-82. (Level I)
9. Grimes DA, Godwin AJ, Rubin A, Smith JA, Lacarra M. Ovulation and follicular development associated with three low-dose oral contraceptives: a randomized controlled trial. *Obstet Gynecol* 1994;83:29-34. (Level I)
10. Stewart FH, Kaunitz AM, Laguardia KD, Karvois DL, Fisher AC, Friedman AJ. Extended use of transdermal norelgestromin/ethinyl estradiol: a randomized trial. *Obstet Gynecol* 2005;105:1389-96. (Level I)
11. LaGuardia KD, Fisher AC, Bainbridge JD, LoCoco JM, Friedman AJ. Suppression of estrogen-withdrawal headache with extended transdermal contraception. *Fertil Steril* 2005;83:1875-7. (Level I)
12. White T, Jain JK, Stanczyk FZ. Effect of oral versus transdermal steroidal contraceptives on androgenic markers. *Am J Obstet Gynecol* 2005;192:2055-9. (Level I)
13. Milsom I, Lete I, Bjertnaes A, Rokstad K, Lindh I, Gruber CJ, et al. Effects on cycle control and bodyweight of the combined contraceptive ring, NuvaRing, versus an oral contraceptive containing 30 microg ethinyl estradiol and 3 mg drospirenone. *Hum Reprod* 2006;21:2304-11. (Level I)
14. Roumen FJ. The contraceptive vaginal ring compared with the combined oral contraceptive pill: a comprehensive review of randomized controlled trials. *Contraception* 2007; 75:420-9. (Level III)
15. Meirik O, Fraser IS, d'Arcangues C. Implantable contraceptives for women. WHO Consultation on Implantable Contraceptives for Women. *Hum Reprod Update* 2003; 9:49-59. (Level III)
16. Braghetto AM, Caserta N, Bahamondes L, Petta CA. Effectiveness of the levonorgestrel-releasing intrauterine system in the treatment of adenomyosis diagnosed and monitored by magnetic resonance imaging. *Contraception* 2007;76:195-9. (Level III)
17. Cho S, Nam A, Kim H, Chay D, Park K, Cho DJ, et al. Clinical effects of the levonorgestrel-releasing intrauterine device in patients with adenomyosis. *Am J Obstet Gynecol* 2008;198:373.e1-373.e7. (Level III)
18. Kaunitz AM. Progestin-releasing intrauterine systems and leiomyoma. *Contraception* 2007;75:S130-3. (Level III)
19. Soysal S, Soysal ME. The efficacy of levonorgestrel-releasing intrauterine device in selected cases of myoma-related menorrhagia: a prospective controlled trial. *Gynecol Obstet Invest* 2005;59:29-35. (Level II-3)
20. Lockhat FB, Emembolu JO, Konje JC. The efficacy, side-effects and continuation rates in women with symptomatic endometriosis undergoing treatment with an intra-uterine administered progestogen (levonorgestrel): a 3 year follow-up. *Hum Reprod* 2005;20:789-93. (Level II-3)
21. Petta CA, Ferriani RA, Abrão MS, Hassan D, Rosa E Silva JC, et al. A 3-year follow-up of women with endometriosis and pelvic pain users of the levonorgestrel-

- releasing intrauterine system. *Eur J Obstet Gynecol Reprod Biol* 2009;143:128–9. (Level I)
22. Abou-Setta AM, Al-Inany HG, Farquhar C. Levonorgestrel-releasing intrauterine device (LNG-IUD) for symptomatic endometriosis following surgery. *Cochrane Menstrual Disorders and Subfertility Group Cochrane Database of Systematic Reviews* 3, 2009. (Meta-analysis)
 23. Lukes AS, Reardon B, Arepally G. Use of the levonorgestrel-releasing intrauterine system in women with hemostatic disorders. *Fertil Steril* 2008;90:673–7. (Level III)
 24. Hubacher D, Grimes DA. Noncontraceptive health benefits of intrauterine devices: a systematic review. *Obstet Gynecol Surv* 2002;57:120–8. (Level III)
 25. Jamieson DJ, Steege JF. The prevalence of dysmenorrhea, dyspareunia, pelvic pain, and irritable bowel syndrome in primary care practices. *Obstet Gynecol* 1996; 87:55–8. (Level II-3)
 26. Hendrix SL, Alexander NJ. Primary dysmenorrhea treatment with a desogestrel-containing low-dose oral contraceptive. *Contraception* 2002;66:393–9. (Level I)
 27. Winkler UH, Ferguson H, Mulders JA. Cycle control, quality of life and acne with two low-dose oral contraceptives containing 20 microg ethinylestradiol. *Contraception* 2004;69:469–76. (Level I)
 28. Milsom I, Sundell G, Andersch B. The influence of different combined oral contraceptives on the prevalence and severity of dysmenorrhea. *Contraception* 1990;42:497–506. (Level II-2)
 29. Hohmann H, Creinin MD. The contraceptive implant. *Clin Obstet Gynecol* 2007;50:907–17. (Level III)
 30. Funk S, Miller MM, Mishell DR Jr, Archer DF, Poindexter A, Schmidt J, et al. Safety and efficacy of Implanon, a single-rod implantable contraceptive containing etonogestrel. *Implanon US Study Group. Contraception* 2005;71:319–26. (Level III)
 31. Croxatto HB. Clinical profile of Implanon: a single-rod etonogestrel contraceptive implant. *Eur J Contracept Reprod Health Care* 2000;5(suppl 2):21–8. (Level III)
 32. Varma R, Sinha D, Gupta JK. Non-contraceptive uses of levonorgestrel-releasing hormone system (LNG-IUS)—a systematic enquiry and overview. *Eur J Obstet Gynecol Reprod Biol* 2006;125:9–28. (Level III)
 33. Harada T, Momoeda M, Taketani Y, Hoshiai H, Terakawa N. Low-dose oral contraceptive pill for dysmenorrhea associated with endometriosis: a placebo-controlled, double-blind, randomized trial. *Fertil Steril* 2008;90:1583–8. (Level I)
 34. Surrey ES. The role of progestins in treating the pain of endometriosis. *J Min Invasive Gynecol* 2006;13:528–34. (Level III)
 35. Walch K, Unfried G, Huber J, Kurz C, van Trotsenburg M, Pernicka E, et al. Implanon versus medroxyprogesterone acetate: effects on pain scores in patients with symptomatic endometriosis—a pilot study. *Contraception* 2009;79:29–34 (Level I)
 36. Fedele L, Bianchi S, Zanonato G, Portuese A, Raffaelli R. Use of a levonorgestrel-releasing intrauterine device in the treatment of rectovaginal endometriosis *Fertility and Sterility* 2001;75:485–488. (Level II-2)
 37. Vercellini P, Frontino G, De Giorgi O, Aimi G, Zaina B, Crosignani PG. Comparison of a levonorgestrel-releasing intrauterine device versus expectant management after conservative surgery for symptomatic endometriosis: a pilot study. *Fertil Steril* 2003;80:305–9. (Level I)
 38. Steinauer J, Autry AM. Extended cycle combined hormonal contraception. *Obstet Gynecol Clin North Am* 2007;34:43–55, viii. (Level III)
 39. Landgren BM, Diczfalusy E. Hormonal effects of the 300 microgram norethisterone (NET) minipill. I. Daily steroid levels in 43 subjects during a pretreatment cycle and during the second month of NET administration. *Contraception* 1980;21:87–113. (Level III)
 40. Kim-Bjorklund T, Landgren BM, Hamberger L. Is the contraceptive effect of 300 micrograms of norethisterone mainly peripheral or central? *Contraception* 1992;45:57–66. (Level II-2)
 41. Archer DF, Jensen JT, Johnson JV, Borisute H, Grubb GS, Constantine GD. Evaluation of a continuous regimen of levonorgestrel/ethinyl estradiol: phase 3 study results. *Contraception* 2006;74:439–45. (Level II-3)
 42. Yonkers KA, Brown C, Pearlstein TB, Foegh M, Sampson-Landers C, Rapkin A. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. *Obstet Gynecol* 2005;106:492–501. (Level I)
 43. Sulak PJ, Scow RD, Preece C, Riggs MW, Kuehl TJ. Hormone withdrawal symptoms in oral contraceptive users. *Obstet Gynecol* 2000;95:261–6. (Level II-3)
 44. Sulak PJ, Kuehl TJ, Ortiz M, Shull BL. Acceptance of altering the standard 21-day/7-day oral contraceptive regimen to delay menses and reduce hormone withdrawal symptoms. *Am J Obstet Gynecol* 2002;186:1142–9. (Level II-3)
 45. Anderson FD, Hait H. A multicenter, randomized study of an extended cycle oral contraceptive [published erratum appears in *Contraception* 2004;69:175]. *Contraception* 2003;68:89–96. (Level I)
 46. Coffee AL, Sulak PJ, Kuehl TJ. Long-term assessment of symptomatology and satisfaction of an extended oral contraceptive regimen. *Contraception* 2007;75:444–9. (Level I)
 47. Sulak PJ, Smith V, Coffee A, Witt I, Kuehl AL, Kuehl TJ. Frequency and management of breakthrough bleeding with continuous use of the transvaginal contraceptive ring: a randomized controlled trial. *Obstet Gynecol* 2008; 112:563–71. (Level I)
 48. Prentice A. Health care implications of dysfunctional uterine bleeding. *Baillieres Best Pract Res Clin Obstet Gynaecol* 1999;13:181–8. (Level III)
 49. McKenna DM, Dockeray CJ, McCann SR. Iron deficiency in pre-menopausal females. *Ir Med J* 1989;82:69–70. (Level III)
 50. Hallberg L, Hogdahl AM, Nilsson L, Rybo G. Menstrual blood loss—a population study. Variation at different ages

- and attempts to define normality. *Acta Obstet Gynecol Scand* 1966;45:320–51. (Level III)
51. Fraser IS, McCarron G. Randomized trial of 2 hormonal and 2 prostaglandin-inhibiting agents in women with a complaint of menorrhagia. *Aust N Z J Obstet Gynaecol* 1991;31:66–70. (Level I)
 52. Larsson G, Milsom I, Lindstedt G, Rybo G. The influence of a low-dose combined oral contraceptive on menstrual blood loss and iron status. *Contraception* 1992;46:327–34. (Level III)
 53. Milman N, Clausen J, Byg KE. Iron status in 268 Danish women aged 18-30 years: influence of menstruation, contraceptive method, and iron supplementation. *Ann Hematol* 1998;77:13–9. (Level II-2)
 54. Braunstein JB, Hausfeld J, Hausfeld J, London A. Economics of reducing menstruation with trimonthly-cycle oral contraceptive therapy: comparison with standard-cycle regimens. *Obstet Gynecol* 2003;102:699–708. (Level III)
 55. Miller L, Notter KM. Menstrual reduction with extended use of combination oral contraceptive pills: randomized controlled trial. *Obstet Gynecol* 2001;98:771–8. (Level I)
 56. Sulak PJ, Carl J, Gopalakrishnan I, Coffee A, Kuehl TJ. Outcomes of extended oral contraceptive regimens with a shortened hormone-free interval to manage breakthrough bleeding. *Contraception* 2004;70:281–7. (Level II-3)
 57. Power J, French R, Cowan F. Subdermal implantable contraceptives versus other forms of reversible contraceptives or other implants as effective methods for preventing pregnancy. *Cochrane Database of Systematic Reviews* 2007, Issue 3. Art. No.: CD001326. DOI: 10.1002/14651858.CD001326.pub2. (Meta-analysis)
 58. Istre O, Trolle B. Treatment of menorrhagia with the levonorgestrel intrauterine system versus endometrial resection. *Fertil Steril* 2001;76:304–9. (Level I)
 59. Barrington JW, Bowen-Simpkins P. The levonorgestrel intrauterine system in the management of menorrhagia. *Br J Obstet Gynaecol* 1997;104:614–6. (Level III)
 60. Tang GW, Lo SS. Levonorgestrel intrauterine device in the treatment of menorrhagia in Chinese women: efficacy versus acceptability. *Contraception* 1995;51:231–5. (Level III)
 61. Andersson JK, Rybo G. Levonorgestrel-releasing intrauterine device in the treatment of menorrhagia. *Br J Obstet Gynaecol* 1990;97:690–4. (Level III)
 62. Ronnerdag M, Odland V. Health effects of long-term use of the intrauterine levonorgestrel-releasing system. A follow-up study over 12 years of continuous use. *Acta Obstet Gynecol Scand* 1999;78:716–21. (Level III)
 63. Crosignani PG, Vercellini P, Mosconi P, Oldani S, Cortesi I, De Giorgi O. Levonorgestrel-releasing intrauterine device versus hysteroscopic endometrial resection in the treatment of dysfunctional uterine bleeding. *Obstet Gynecol* 1997;90:257–63. (Level I)
 64. Varila E, Wahlstrom T, Rauramo I. A 5-year follow-up study on the use of a levonorgestrel intrauterine system in women receiving hormone replacement therapy. *Fertil Steril* 2001;76:969–73. (Level III)
 65. Hurskainen R, Paavonen J. Levonorgestrel-releasing intrauterine system in the treatment of heavy menstrual bleeding. *Curr Opin Obstet Gynecol* 2004;16:487–90. (Level III)
 66. Lethaby A, Cooke I, Rees MC. Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding. *Cochrane Database of Systematic Reviews* 2005, Issue 4. Art. No.: CD002126. DOI: 10.1002/14651858.CD002126.pub2. (Meta-analysis)
 67. Kaunitz AM, Meredith S, Inki P, Kubba A, Sanchez-Ramos L. Levonorgestrel-releasing intrauterine system and endometrial ablation in heavy menstrual bleeding: a systematic review and meta-analysis. *Obstet Gynecol* 2009;113:1104–16 (Meta-analysis)
 68. Marjoribanks J, Lethaby A, Farquhar C. Surgery versus medical therapy for heavy menstrual bleeding. *Cochrane Database of Systematic Reviews* 2006, Issue 2. Art. No.: CD003855. DOI: 10.1002/14651858.CD003855.pub2. (Meta-analysis)
 69. Blumenthal PD, Trussell J, Singh RH, Guo A, Borenstein J, Dubois RW, et al. Cost-effectiveness of treatments for dysfunctional uterine bleeding in women who need contraception. *Contraception* 2006;74:249–58. (Level III)
 70. Bancroft J, Rennie D. The impact of oral contraceptives on the experience of perimenstrual mood, clumsiness, food craving and other symptoms. *J Psychosom Res* 1993;37:195–202. (Level II-3)
 71. Joffe H, Cohen LS, Harlow BL. Impact of oral contraceptive pill use on premenstrual mood: predictors of improvement and deterioration. *Am J Obstet Gynecol* 2003;189:1523–30. (Level II-3)
 72. Andersch B. The effect of various oral contraceptive combinations on premenstrual symptoms. *Int J Gynaecol Obstet* 1982;20:463–9. (Level II)
 73. Graham CA, Sherwin BB. A prospective treatment study of premenstrual symptoms using a triphasic oral contraceptive. *J Psychosom Res* 1992;36:257–66. (Level II-2)
 74. Reid RL, Case AM. Premenstrual syndrome and menstrual-related disorders. In: Falcone T, Hurd WW, editors. *Clinical reproductive medicine and surgery*. Philadelphia (PA): Mosby Elsevier; 2007. p. 335–51. (Level III)
 75. Freeman EW, Kroll R, Rapkin A, Pearlstein T, Brown C, Parsey K, et al. Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder. PMS/PMDD Research Group. *J Womens Health Gend Based Med* 2001;10:561–9. (Level II-1)
 76. Pearlstein TB, Bachmann GA, Zacur HA, Yonkers KA. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. *Contraception* 2005;72:414–21. (Level II-3)
 77. Joffe H, Petrillo LF, Viguera AC, Gottschall H, Soares CN, Hall JE, et al. Treatment of premenstrual worsening of depression with adjunctive oral contraceptive pills: a preliminary report. *J Clin Psychiatry* 2007;68:1954–62. (Level I)
 78. Coffee AL, Kuehl TJ, Willis S, Sulak PJ. Oral contraceptives and premenstrual symptoms: Comparison of a 21/7 and extended regimen. *AJOG* 2006;156:1311–9. (Level II-2)

79. Case AM, Reid RL. Effects of the menstrual cycle on medical disorders. *Arch Intern Med* 1998;158:1405–12. (Level III)
80. Digre K, Damasio H. Menstrual migraine: differential diagnosis, evaluation, and treatment. *Clin Obstet Gynecol* 1987;30:417–30. (Level III)
81. Granella F, Sances G, Zanferrari C, Costa A, Martignoni E, Manzoni GC. Migraine without aura and reproductive life events: a clinical epidemiological study in 1300 women. *Headache* 1993;33:385–9. (Level III)
82. Nelson AL. Extended-cycle oral contraception: a new option for routine use. *Treat Endocrinol* 2005;4:139–45. (Level III)
83. Batukan C, Muderris II. Efficacy of a new oral contraceptive containing drospirenone and ethinyl estradiol in the long-term treatment of hirsutism. *Fertil Steril* 2006; 85:436–40. (Level I)
84. Breitkopf DM, Rosen MP, Young SL, Nagamani M. Efficacy of second versus third generation oral contraceptives in the treatment of hirsutism. *Contraception* 2003; 26:349–53. (Level I)
85. Arowojolu AO, Gallo MF, Lopez LM, Grimes DA, Garner SE. Combined oral contraceptive pills for treatment of acne. *Cochrane Database of Systematic Reviews* 2009, Issue 3. Art. No.: CD004425. DOI: 10.1002/14651858.CD004425.pub4. (Meta-analysis)
86. Kaufman DW, Shapiro S, Slone D, Rosenberg L, Miettinen OS, Stolley PD, et al. Decreased risk of endometrial cancer among oral-contraceptive users. *N Engl J Med* 1980;303:1045–7. (Level II-2)
87. Kelsey JL, LiVolsi VA, Holford TR, Fischer DB, Mostow ED, Schwartz PE, et al. A case-control study of cancer of the endometrium. *Am J Epidemiol* 1982; 116:333–42. (Level II-2)
88. Hulka BS, Chambless LE, Kaufman DG, Fowler WC Jr, Greenberg BG. Protection against endometrial carcinoma by combination-product oral contraceptives. *JAMA* 1982;247:475–7. (Level II-2)
89. Jick SS, Walker AM, Jick H. Oral contraceptives and endometrial cancer. *Obstet Gynecol* 1993;82:931–5. (Level II-2)
90. Weiderpass E, Adami HO, Baron JA, Magnusson C, Lindgren A, Persson I. Use of oral contraceptives and endometrial cancer risk (Sweden). *Cancer Causes Control* 1999;10:277–84. (Level II-2)
91. La Vecchia C, Altieri A, Franceschi S, Tavani A. Oral contraceptives and cancer : An update. *Drug Safety* 2001; 24:741–54. (Level III)
92. Centers for Disease Control. Oral contraceptive use and the risk of endometrial cancer. *JAMA* 1983;249:1600–04. (Level II-2)
93. Henderson BE, Casagrande JT, Pike MC, Mack T, Rosario I, Duke A. The epidemiology of endometrial cancer in young women. *Br J Cancer* 1983;47:749–56. (Level II-2)
94. Stanford JL, Brinton LA, Berman ML, Mortel R, Twigg LB, Barrett RJ, et al. Oral contraceptives and endometrial cancer: do other risk factors modify the association? *Int J Cancer* 1993;54:243–8. (Level II-2)
95. Schlesselman JJ. Risk of endometrial cancer in relation to use of combined oral contraceptives. A practitioner's guide to meta-analysis. *Hum Reprod* 1997;12:1851–63. (Level III)
96. Vessey M, Painter R, Yeates D. Mortality in relation to oral contraceptive use and cigarette smoking. *Lancet* 2003;362:185–91. (Level II-2)
97. Voigt LF, Deng Q, Weiss NS. Recency, duration, and progestin content of oral contraceptives in relation to the incidence of endometrial cancer (Washington, USA). *Cancer Causes Control* 1994;5:227–33. (Level III)
98. Rosenblatt KA, Thomas DB. Hormonal content of combined oral contraceptives in relation to the reduced risk of endometrial carcinoma. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives. *Int J Cancer* 1991;49:870–4. (Level II-2)
99. Depot-medroxyprogesterone acetate (DMPA) and risk of endometrial cancer. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives. *Int J Cancer* 1991;49:186–90. (Level II-2)
100. Kaunitz AM. Depot medroxyprogesterone acetate contraception and the risk of breast and gynecologic cancer. *J Reprod Med* 1996;41:419–27. (Level III)
101. Nilsson CG, Haukkamaa M, Vierola H, Luukkainen T. Tissue concentrations of levonorgestrel in women using levonorgestrel-releasing IUD. *Clin Endocrinol* 1982;17: 529–36. (Level II-3)
102. Sturdee D. Levonorgestrel intrauterine system for endometrial protection. *J Br Menopause Soc* 2006;(suppl 1): 1–3. (Level III)
103. Haimovich S, Checa MA, Mancebo G, Fuste P, Carreras R. Treatment of endometrial hyperplasia without atypia in peri- and postmenopausal women with a levonorgestrel intrauterine device. *Menopause* 2008;15:1002–4. (Level III)
104. Varma R, Soneja H, Bhatia K, Ganesan R, Rollason T, Clark TJ, et al. The effectiveness of a levonorgestrel-releasing intrauterine system (LNG-IUS) in the treatment of endometrial hyperplasia--a long-term follow-up study. *Eur J Obstet Gynecol Reprod Biol* 2008;139:169–75. (Level II)
105. Wildemeersch D, Janssens D, Pyllyser K, De Wever N, Verbeeck G, Dhont M, et al. Management of patients with non-atypical and atypical endometrial hyperplasia with a levonorgestrel-releasing intrauterine system: long-term follow-up. *Maturitas* 2007;57:210–3. (Level III)
106. Buttini MJ, Jordan SJ, Webb PM. The effect of the levonorgestrel releasing intrauterine system on endometrial hyperplasia: an Australian study and systematic review. *Aust N Z J Obstet Gynaecol* 2009;49:316–22 (systematic review)
107. Kresowik J, Ryan GL, Van Voorhis BJ. Progression of atypical endometrial hyperplasia to adenocarcinoma despite intrauterine progesterone treatment with the levonorgestrel-releasing intrauterine system. *Obstet Gynecol* 2008;111:547–9. (Level III)

108. Clark TJ, Neelakantan D, Gupta JK. The management of endometrial hyperplasia: An evaluation of current practice. *EJOG* 2006;125:259–64. (Level III)
109. Chan SS, Tam WH, Yeo W, Yu MM, Ng DP, Wong AW, et al. A randomised controlled trial of prophyllactic levonorgestrel intrauterine system in tamoxifen-treated women. *BJOG* 2007;114:1510–5. (Level I)
110. Collaborative Group on Epidemiological Studies of Ovarian Cancer. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. *Lancet* 2008;371:303–14. (Meta-analysis)
111. Ness RB, Grisso JA, Klapper J, Schlesselman JJ, Silberzweig S, Vergona R, et al. Risk of ovarian cancer in relation to estrogen and progestin dose and use characteristics of oral contraceptives. SHARE Study Group. *Steroid Hormones and Reproductions. Am J Epidemiol* 2000;152:233–41. (Level II-2)
112. Grenader T, Peretz T, Lifchitz M, Shavit L. BRCA1 and BRCA2 germ-line mutations and oral contraceptives: to use or not to use. *Breast* 2005;14:264–8. (Level III)
113. Fernandez E, La Vecchia C, Balducci A, Chatenoud L, Franceschi S, Negri E. Oral contraceptives and colorectal cancer risk: a meta-analysis. *Br J Cancer* 2001;84:722–7. (Meta-analysis)
114. Hannaford P, Elliott A. Use of exogenous hormones by women and colorectal cancer: evidence from the Royal College of General Practitioners' Oral Contraception Study. *Contraception* 2005;71:95–8. (Level II-2)
115. Christensen JT, Boldsen JL, Westergaard JG. Functional ovarian cysts in premenopausal and gynecologically healthy women. *Contraception* 2002;66:153–7. (Level III)
116. Holt VL, Daling JR, McKnight B, Moore D, Stergachis A, Weiss NS. Functional ovarian cysts in relation to the use of monophasic and triphasic oral contraceptives. *Obstet Gynecol* 1992;79:529–33. (Level II-2)
117. Steinkampf MP, Hammond KR, Blackwell RE. Hormonal treatment of functional ovarian cysts: a randomized, prospective study. *Fertil Steril* 1990;54:775–7. (Level I)
118. Turan C, Zorlu CG, Ugur M, Ozcan T, Kaleli B, Gokmen O. Expectant management of functional ovarian cysts: an alternative to hormonal therapy. *Int J Gynaecol Obstet* 1994;47:257–60. (Level II-1)
119. MacKenna A, Fabres C, Alam V, Morales V. Clinical management of functional ovarian cysts: a prospective and randomized study. *Hum Reprod* 2000;15:2567–9. (Level I)
120. Bayar U, Barut A, Ayoglu F. Diagnosis and management of simple ovarian cysts. *Int J Gynaecol Obstet* 2005;91:187–8. (Level II-1)
121. Tayob Y, Adams J, Jacobs HS, Guillebaud J. Ultrasound demonstration of increased frequency of functional ovarian cysts in women using progestogen-only oral contraception. *Br J Obstet Gynaecol* 1985;92:1003–9. (Level-II-3)
122. Hidalgo MM, Lisondo C, Juliato CT, Espejo-Arce X, Monteiro I, Bahamondes L. Ovarian cysts in users of Implanon and Jadelle subdermal contraceptive implants. *Contraception* 2006;73:532–6. (Level II-3)
123. Grimes DA, Schulz KF. Surrogate end points in clinical research: hazardous to your health. *Obstet Gynecol* 2005;105:1114–8. (Level III)
124. Kleerekoper M, Brienza RS, Schultz LR, Johnson CC. Oral contraceptive use may protect against low bone mass. Henry Ford Hospital Osteoporosis Cooperative Research Group. *Arch Intern Med* 1991;151:1971–6. (Level II-3)
125. Lindsay R, Tohme J, Kandars B. The effect of oral contraceptive use on vertebral bone mass in pre- and postmenopausal women. *Contraception* 1986;34:333–40. (Level II-2)
126. Lloyd T, Buchanan JR, Ursino GR, Myers C, Woodward G, Halbert DR. Long-term oral contraceptive use does not affect trabecular bone density. *Am J Obstet Gynecol* 1989;160:402–4. (Level II-2)
127. Lloyd T, Taylor DS, Lin HM, Matthews AE, Egli DF, Legro RS. Oral contraceptive use by teenage women does not affect peak bone mass: a longitudinal study. *Fertil Steril* 2000;74:734–8. (Level II-2)
128. Garnero P, Sornay-Rendu E, Delmas PD. Decreased bone turnover in oral contraceptive users. *Bone* 1995;16:499–503. (Level II-2)
129. Enzelsberger H, Metka M, Heytmanek G, Schurz B, Kurz C, Kusztrich M. Influence of oral contraceptive use on bone density in climacteric women. *Maturitas* 1988;9:375–8. (Level III)
130. Recker RR, Davies KM, Hinders SM, Heaney RP, Stegman MR, Kimmel DB. Bone gain in young adult women. *JAMA* 1992;268:2403–8. (Level II-2)
131. Gambacciani M, Ciaponi M, Cappagli B, Benussi C, Genazzani AR. Longitudinal evaluation of perimenopausal femoral bone loss: effects of a low-dose oral contraceptive preparation on bone mineral density and metabolism. *Osteoporos Int* 2000;11:544–8. (Level I)
132. Hartard M, Bottermann P, Bartenstein P, Jeschke D, Schwaiger M. Effects on bone mineral density of low-dosed oral contraceptives compared to and combined with physical activity. *Contraception* 1997;55:87–90. (Level II-3)
133. Kuohung W, Borgatta L, Stubblefield P. Low-dose oral contraceptives and bone mineral density: an evidence-based analysis. *Contraception* 2000;61:77–82. (Level III)
134. Martins SL, Curtis KM, Glasier AF. Combined hormonal contraception and bone health: a systematic review. *Contraception* 2006;73:445–69. (Meta-analysis)
135. Teegarden D, Legowski P, Gunther CW, McCabe GP, Peacock M, Lyle RM. Dietary calcium intake protects women consuming oral contraceptives from spine and hip bone loss. *J Clin Endocrinol Metab* 2005;90:5127–33. (Level I)
136. Lopez LM, Grimes DA, Schulz KF, Curtis KM. Steroidal contraceptives: effect on bone fractures in women. *Cochrane Database of Systematic Reviews* 2009, Issue 2. Art. No.: CD006033. DOI: 10.1002/14651858.CD006033.pub3. (Meta-analysis)
137. La Vecchia C, Tavani A, Gallus S. Oral contraceptives and risk of hip fractures. *Lancet* 1999;354:335–6. (Level III)

138. Mallmin H, Ljunghall S, Persson I, Bergstrom R. Risk factors for fractures of the distal forearm: a population-based case-control study. *Osteoporos Int* 1994;4:298–304. (Level II-2)
139. Tuppurainen M, Kroger H, Saarikoski S, Honkanen R, Alhava E. The effect of previous oral contraceptive use on bone mineral density of perimenopausal women. *Osteoporosis International* 1994;4:93–8. (Level II-3)
140. Cooper C, Hannaford P, Croft P, Kay CR. Oral contraceptive pill use and fractures in women: a prospective study. *Bone* 1993;14:41–5. (Level II-2)
141. Barad D, Kooperberg C, Wactawski-Wende J, Liu J, Hendrix SL, Watts NB. Prior oral contraception and postmenopausal fracture: a Women's Health Initiative observational cohort study. *Fertil Steril* 2005;84:374–83. (Level II-2)
142. Vessey M, Mant J, Painter R. Oral contraception and other factors in relation to hospital referral for fracture. Findings in a large cohort study. *Contraception* 1998;57:231–5. (Level II-2)
143. Johansson C, Mellstrom D. An earlier fracture as a risk factor for new fracture and its association with smoking and menopausal age in women. *Maturitas* 1996;24:97–106. (Level II-2)
144. O'Neill TW, Marsden D, Adams JE, Silman AJ. Risk factors, falls, and fracture of the distal forearm in Manchester, UK. *J Epidemiol Community Health* 1996;50:288–92. (Level II-2)
145. O'Neill TW, Silman AJ, Naves Diaz M, Cooper C, Kanis J, Felsenberg D. Influence of hormonal and reproductive factors on the risk of vertebral deformity in European women. *European Vertebral Osteoporosis Study Group. Osteoporos Int* 1997;7:72–8. (Level II-3)
146. Massai R, Makarainen L, Kuukankorpi A, Klipping C, Duijkers I, Dieben T. The combined contraceptive vaginal ring and bone mineral density in healthy pre-menopausal women. *Hum Reprod* 2005;20:2764–8. (Level II-1)
147. Cundy T, Cornish J, Roberts H, Elder H, Reid IR. Spinal bone density in women using depot medroxyprogesterone contraception. *Obstet Gynecol* 1998;92:569–73. (Level II-3)
148. Di X, Li Y, Zhang C, Jiang J, Gu S. Effects of levonorgestrel-releasing subdermal contraceptive implants on bone density and bone metabolism. *Contraception* 1999; 60:161–6. (Level I)
149. Bahamondes L, Monteiro-Dantas C, Espejo-Arce X, Dos Santos Fernandes AM, Lui-Filho JF, Perrotti M, et al. A prospective study of the forearm bone density of users of etonorgestrel- and levonorgestrel-releasing contraceptive implants. *Hum Reprod* 2006;21:466–70. (Level I)
150. Berenson AB, Rahman M, Breitkopf CR, Bi LX. Effects of depot medroxyprogesterone acetate and 20-microgram oral contraceptives on bone mineral density. *Obstet Gynecol* 2008;112:788–99. (Level II-3)
151. Gourlay ML, Brown SA. Clinical considerations in premenopausal osteoporosis. *Arch Intern Med* 2004;164:603–14. (Level III)
152. Kaunitz AM. Depo-Provera's black box: time to reconsider? *Contraception* 2005;72:165–7. (Level III)
153. Rosenberg L, Zhang Y, Constant D, Cooper D, Kalla AA, Micklesfield L, et al. Bone status after cessation of use of injectable progestin contraceptives. *Contraception* 2007;76:425–31. (Level II-2)
154. Parazzini F, Negri E, La Vecchia C, Fedele L, Rabaiotti M, Luchini L. Oral contraceptive use and risk of uterine fibroids. *Obstet Gynecol* 1992;79:430–3. (Level II-2)
155. Chiaffarino F, Parazzini F, La Vecchia C, Marsico S, Surace M, Ricci E. Use of oral contraceptives and uterine fibroids: results from a case-control study. *Br J Obstet Gynaecol* 1999;106:857–60. (Level II-2)
156. Ross RK, Pike MC, Vessey MP, Bull D, Yeates D, Casagrande JT. Risk factors for uterine fibroids: reduced risk associated with oral contraceptives [published erratum appears in *Br Med J* 1986;293:1027]. *Br Med J* 1986;293:359–62. (Level II-2)
157. Wise LA, Palmer JR, Harlow BL, Spiegelman D, Stewart EA, Adams-Campbell LL, et al. Reproductive factors, hormonal contraception, and risk of uterine leiomyomata in African-American women: a prospective study. *Am J Epidemiol* 2004;159:113–23. (Level II-2)
158. Marshall LM, Spiegelman D, Goldman MB, Manson JE, Colditz GA, Barbieri RL, et al. A prospective study of reproductive factors and oral contraceptive use in relation to the risk of uterine leiomyomata. *Fertil Steril* 1998;70:432–9. (Level II-2)
159. Carr BR, Marshburn PB, Weatherall PT, Bradshaw KD, Breslau NA, Byrd W, et al. An evaluation of the effect of gonadotropin-releasing hormone analogs and medroxyprogesterone acetate on uterine leiomyomata volume by magnetic resonance imaging: a prospective, randomized, double blind, placebo-controlled, crossover trial. *J Clin Endocrinol Metab* 1993;76:1217–23. (Level II-3)
160. Magalhaes J, Aldrighi JM, de Lima GR. Uterine volume and menstrual patterns in users of the levonorgestrel-releasing intrauterine system with idiopathic menorrhagia or menorrhagia due to leiomyomas. *Contraception* 2007;75:193–8. (Level II-2)

The MEDLINE database, the Cochrane Library, and the American College of Obstetricians and Gynecologists' own internal resources and documents were used to conduct a literature search to locate relevant articles published between January 1995 and November 2007. The search was restricted to articles published in the English language. Priority was given to articles reporting results of original research, although review articles and commentaries also were consulted. Abstracts of research presented at symposia and scientific conferences were not considered adequate for inclusion in this document. Guidelines published by organizations or institutions such as the National Institutes of Health and the American College of Obstetricians and Gynecologists were reviewed, and additional studies were located by reviewing bibliographies of identified articles. When reliable research was not available, expert opinions from obstetrician-gynecologists were used.

Studies were reviewed and evaluated for quality according to the method outlined by the U.S. Preventive Services Task Force:

- I Evidence obtained from at least one properly designed randomized controlled trial.
- II-1 Evidence obtained from well-designed controlled trials without randomization.
- II-2 Evidence obtained from well-designed cohort or case-control analytic studies, preferably from more than one center or research group.
- II-3 Evidence obtained from multiple time series with or without the intervention. Dramatic results in uncontrolled experiments also could be regarded as this type of evidence.
- III Opinions of respected authorities, based on clinical experience, descriptive studies, or reports of expert committees.

Based on the highest level of evidence found in the data, recommendations are provided and graded according to the following categories:

Level A—Recommendations are based on good and consistent scientific evidence.

Level B—Recommendations are based on limited or inconsistent scientific evidence.

Level C—Recommendations are based primarily on consensus and expert opinion.

Copyright January 2010 by the American College of Obstetricians and Gynecologists. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, posted on the Internet, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without prior written permission from the publisher.

Requests for authorization to make photocopies should be directed to Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923, (978) 750-8400.

ISSN 1099-3630

**The American College of Obstetricians and Gynecologists
409 12th Street, SW, PO Box 96920, Washington, DC 20090-6920**

Noncontraceptive uses of hormonal contraceptives. Practice Bulletin No. 110. American College of Obstetricians and Gynecologists. *Obstet Gynecol* 2010;115:206–18.